CLOCK and acute myeloid leukemia: The assessment using the Pan‐tissue clock and CausAge revealed significant EAAs in AML patients compared to those of the control cohort [5], with mean EAAs of 20.0 and 29.5 years, respectively (Figure 1A; Figure S1; both adj.